Application of the combination of TFF2 protein and IFN-κ protein in the treatment of novel coronavirus infection
The combination of TFF2 protein and IFN-κ protein provides a safer and more effective treatment for novel coronavirus infection, outperforming existing therapies by accelerating symptom relief and reducing hospitalization time with minimal side effects.
Patent Information
- Application Number
- JP2022559919
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-03-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-03-30
AI Technical Summary
Current antiviral therapies for novel coronavirus infection face challenges such as toxicity, side effects, and the unpredictability of drug interactions when combining multiple drugs, necessitating the development of more effective and safer treatments.
A combination therapy using TFF2 protein and IFN-κ protein, administered via aerosol inhalation, nasal drops, or other routes, to treat novel coronavirus infection and related diseases, with specific dosages and ratios to enhance therapeutic efficacy.
The combination of TFF2 protein and IFN-κ protein demonstrates superior therapeutic effects in treating novel coronavirus infection, reducing symptoms, shortening recovery time, and minimizing side effects compared to existing treatments like hydroxychloroquine, while maintaining low toxicity.
Smart Images

Figure 0007579880000004 
Figure 0007579880000005 
Figure 0007579880000006
Abstract
Description
[Technical field]
[0001] The present disclosure belongs to the field of biotechnology and medicine. Specifically, the present disclosure relates to a combination of TFF2 protein and IFN-κ, its application in the preparation of a product for treating novel coronavirus infection and its related diseases, and a method for treating novel coronavirus infection and its related diseases with the product. [Background technology]
[0002] Background technology Corona Virus Disease 2019 (COVID-19), commonly known as "COVID-19", refers to pneumonia caused by the 2019 novel coronavirus infection. The clinical symptoms of COVID-19 are mainly fever, dry cough, and fatigue, and a small number of patients also have symptoms such as nasal congestion, runny nose, sore throat, muscle pain, and diarrhea. Severe patients often develop dyspnea and hypoxemia within one week of onset, and when the disease becomes severe, it rapidly progresses to acute respiratory distress syndrome, septic shock, difficult-to-correct metabolic acidosis, coagulation disorders, and multiple organ failure. It is important to note that severe and critical patients may have a moderate low-grade fever or even no obvious fever during the course of the disease.
[0003] From December 2019 to March 30, 2020, a total of 82,451 cases of novel coronavirus pneumonia have been diagnosed in China, a total of 638,946 cases have been diagnosed overseas, a total of 33,953 people have died worldwide, and more than 180 countries and regions have confirmed cases of novel coronavirus infections worldwide, and the global epidemic is still ongoing. On March 11, 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization. On March 25, 2020, the United Nations launched the Global COVID-19 Humanitarian Response Plan, which aims to help the world's most vulnerable countries fight the pandemic, protect millions of lives, and prevent the virus from continuing to spread across countries.
[0004] These data fully demonstrate that the novel coronavirus infection has caused a serious global pandemic, the social and even global damage of which is enormous and requires great attention.
[0005] The novel coronavirus (2019-nCoV), which causes novel coronavirus pneumonia, is an enveloped betacoronavirus and the seventh coronavirus known to infect humans, the other six being HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV (which causes severe acute respiratory syndrome), and MERS-CoV (which causes Middle East respiratory syndrome).
[0006] Although both belong to the coronavirus, the new coronavirus has many different properties and symptoms from other coronaviruses. For example, the differences between the new coronavirus infection and the SARS virus infection include: (a) in terms of genetic characteristics, the genetic characteristics of the new coronavirus are significantly different from SARS-CoV (and MERS-CoV), and the homology with bat SARS-like coronaviruses is more than 85%; (b) in terms of clinical symptoms, SARS-CoV can cause severe acute respiratory syndrome, the main symptoms of which are fever, cough, headache, muscle pain, and symptoms of respiratory tract infection, while the new coronavirus has a slow onset, relatively mild symptoms, and is more concealing; (c) in terms of infectivity, the SARS virus has symptoms such as fever and pneumonia after infection and is highly infectious, while the new coronavirus has an incubation period of about 10 days or more and is infectious during the incubation period. Therefore, further investigation and research are needed for the prevention and treatment of COVID-19.
[0007] According to the "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)", China's current drug treatment for novel coronavirus pneumonia mainly includes: antiviral therapy using antiviral drugs such as alpha-interferon, lopinavir / ritonavir, ribavirin, chloroquine phosphate, arbidol, etc.; immunotherapy using tocilizumab, etc.; traditional Chinese medicine treatment using Chinese herbal medicines such as Huo Xiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Qingwen Detoxification Capsules, and Qingfei Paidu Tang, etc. Among these drugs, chloroquine and Lianhua Qingwen Capsules are particularly effective (according to the experience and data shared by academician Zhong Nanshan at the China-Europe Anti-Infectious Disease Exchange Conference on March 25). In addition, clinical drug research has shown that hydroxychloroquine (also known as hydrochloroquine) can shorten the detoxification time and has lower toxicity than chloroquine phosphate, and is the currently recommended drug for treating novel coronavirus pneumonia.
[0008] However, current antiviral therapies may bring certain toxicities and side effects to the human body and may lead to the emergence of drug-resistant virus strains. However, herbal treatments may have different levels of acceptance in different countries around the world due to the unclear active substances and mechanisms.
[0009] Therefore, although some preventive measures and some experience have been gained in the process of fighting viruses such as the early SARS and the months of fighting the new coronavirus pneumonia, there is still an urgent need to develop more effective therapeutic drugs to suppress the further occurrence and spread of the new coronavirus infection in order to maintain the health and safety of all mankind.
[0010] Combination therapy effects are unpredictable When two or more drugs are used in combination to prevent or treat a particular disease, many potential problems can arise. The in vivo interactions between two drugs are complex. The effect of any single drug is related to its absorption, distribution, and excretion. When two drugs are introduced into the body, one drug affects the absorption, distribution, and excretion of the other drug, thus altering the effect of the other drug. For example, one drug may inhibit, activate, or induce the production of enzymes involved in the metabolic pathway of the excretion of the other drug. For example, the combination of natalizumab and interferon beta-1-a has been reported to increase the risk of unexpected side effects (Rudick et al., New England Journal of Medicine, 354, 911-923, 2006; Kleinschmidt-DeMasters, New England Journal of Medicine, 353, 369-379, 2005; Langer-Gould, New England Journal of Medicine, 353, 369-379, 2005). Similar examples abound in the development of combination therapies.
[0011] Therefore, when two or more drugs are administered to treat the same disease, it is difficult to predict whether each drug will complement, be ineffective, or interfere with the therapeutic effect of the other drug in the subject. The interaction between two drugs not only affects the intended therapeutic effect of each drug, but also increases the level of toxic metabolites. This interaction also increases or decreases the side effects of each drug. When two drugs are administered to treat a disease, it is difficult to predict how the adverse effects of each drug will change. It is also difficult to accurately predict when the effects of the interaction between the two drugs will appear. Summary of the Invention [Problem to be solved by the invention]
[0012] Thus, the state of the art at the time of filing is that the efficacy of combination therapy of two particular drugs cannot be predicted until the results of combination trials are available.
[0013] Thus, there is an urgent need in the art to develop drugs that can effectively treat novel coronavirus infection and its associated diseases. [Means for solving the problem]
[0014] Contents of the invention The present disclosure provides products or combinations that can effectively treat novel coronavirus infection and its associated symptoms.
[0015] In one aspect of the present disclosure, an article of manufacture is provided that includes: (a) TFF2 protein; (b) IFN-κ protein; and (c) An optional pharma- ceutically acceptable carrier.
[0016] In some embodiments, the article of manufacture is a pharmaceutical composition, a formulation combination, or a kit.
[0017] In some embodiments, the TFF2 protein is selected from the following: a polypeptide comprising the sequence SEQ ID NO:1 or 2, or a polypeptide comprising a sequence encoded by a nucleic acid molecule set forth in any one of SEQ ID NOs:3-6, or a polypeptide having at least 80% homology (e.g. at least 85%, 85%, 90%, 95%, 96%, 97%, 98%, 99% homology) to said polypeptide and having inflammation modulating activity, or a polypeptide derived from said polypeptide and having inflammation modulating activity; the IFN-κ protein is selected from the following: a human IFN-κ protein or a mouse IFN-κ protein, such as a protein set forth in the sequence SEQ ID NO:7 or 8, or a polypeptide encoded by a nucleic acid molecule set forth in any one of SEQ ID NOs:9-12.
[0018] In some embodiments, the TFF2 protein is selected from a human TFF2 protein or a mouse TFF2 protein. In some embodiments, the TFF2 protein is selected from a polypeptide set forth in sequence SEQ ID NO:1 or 2, or a polypeptide encoded by a nucleic acid molecule set forth in any one of SEQ ID NO:3-6.
[0019] In some embodiments, the IFN-κ protein is selected from the following: a polypeptide comprising the sequence SEQ ID NO:7 or 8, or a polypeptide comprising a sequence encoded by a nucleic acid molecule set forth in any one of SEQ ID NOs:9-12, or a polypeptide having at least 80% homology (e.g., at least 85%, 85%, 90%, 95%, 96%, 97%, 98%, 99% homology) to said polypeptides and having antiviral activity (e.g., inhibiting the replication of a virus such as a novel coronavirus), or a polypeptide derived from said polypeptides and having antiviral activity (e.g., inhibiting the replication of a virus such as a novel coronavirus).
[0020] In some embodiments, the IFN-κ protein is selected from a human IFN-κ protein or a mouse IFN-κ protein. In some embodiments, the IFN-κ protein is selected from a protein set forth in sequence SEQ ID NO:7 or 8, or a polypeptide encoded by a nucleic acid molecule set forth in any one of SEQ ID NOs:9-12.
[0021] In some embodiments, the amount of the TFF2 protein is 0.1 to 100 mg, 0.5 to 50 mg, 1 to 40 mg, or 5 to 30 mg.
[0022] In some embodiments, the amount of the IFN-κ protein is 0.01 to 100 mg, 0.05 to 80 mg, 0.1 to 70 mg, or 0.5 to 50 mg. Alternatively, the amount of the IFN-κ protein is 1x10 4 ~1x10 8 Activity units, 5x104 ~5x10 7 Activity unit, 1x10 5 ~1x10 7 Activity units, 5x10 5 ~5x10 6 It is an activity unit.
[0023] In some embodiments, the mass ratio of TFF2 protein to IFN-κ protein is 1:100 to 100:1, 1:50 to 50:1, 1:10 to 10:1, 1:5 to 5:1, 1:2 to 2.5:1, or 1:1 to 2:1.
[0024] In some embodiments, the above product forms are suitable for administration of the TFF2 protein and the IFN-κ protein by the same or different routes selected from the group consisting of: aerosol inhalation, nasal drops, spray, intravenous administration, administration into a target tissue or oral administration.
[0025] In some embodiments, the above product forms are suitable for simultaneous, sequential or spaced administration of the TFF2 protein and the IFN-κ protein.
[0026] In some embodiments, the above article of manufacture further comprises: one or more containers containing the TFF2 protein and the IFN-protein, e.g., one or more containers containing unit doses of the TFF2 protein and the IFN-protein; an apparatus for administration; instructions guiding use, etc.
[0027] In one aspect of the present disclosure, there is provided an application of a TFF2 protein and an IFN-κ protein in the preparation of a product of the present disclosure, wherein said product is used for treating a novel coronavirus infection and its associated diseases in a subject.
[0028] In some embodiments, the novel coronavirus infection and its associated diseases include: novel coronavirus pneumonia; one or more diseases associated with novel coronavirus infection selected from the group consisting of: dyspnea, hypoxemia, acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation disorders, multiple organ failure, pulmonary fibrosis, chronic inflammation with long-term onset, fever, dry cough, fatigue, stuffy nose, runny nose, sore throat, muscle pain, and diarrhea.
[0029] In some embodiments, the subject is a human. In another aspect of the present disclosure, there is provided a method for treating a novel coronavirus infection and its associated diseases in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a combination of a TFF2 protein and an IFN-κ protein. Features included in this aspect are as described above.
[0030] In another aspect of the present disclosure, there is provided a combination of TFF2 protein and IFN-κ protein for use in treating a subject with novel coronavirus infection and its associated diseases. The features included in this aspect are as described above.
[0031] Those skilled in the art can arbitrarily combine the above technical solutions and technical features without departing from the concept and protection scope of the present disclosure. Based on other contents of the present disclosure, other aspects of the present invention will be obvious to those skilled in the art.
[0032] The present disclosure is further described below with reference to the accompanying drawings, which are intended only to illustrate embodiments of the present disclosure and are not intended to limit the scope of the present disclosure. [Brief description of the drawings]
[0033] [Figure 1A] FIG. 1A shows an SDS-PAGE electropherogram of TFF2 protein. [Figure 1B]FIG. 1B shows functional activity test of TFF2 protein: OD450 logistic fit curves of TFF protein stimulated proliferation of MCF7 cells in vitro. [Figure 2A] FIG. 2A shows an SDS-PAGE electropherogram of IFN-κ protein. [Figure 2B] FIG. 2B shows an in vitro functional activity assay of IFN-κ protein: IFN-κ protein inhibits influenza virus PR8 replication in A549 cell line. [Diagram 3] FIG. 3 shows the percentage of novel coronavirus patients who experienced clinical improvement by combination of TFF2 protein and IFN-κ protein. [Figure 4] Figure 4 shows the nucleic acid negativity rate of novel coronavirus patients treated with a combination of TFF2 protein and IFN-κ protein. [Diagram 5] Figure 5 shows the number of days required to improve CT images of novel coronavirus patients by combining TFF2 protein with IFN-κ protein. [Figure 6] FIG. 6 shows the number of days required to eliminate cough in novel coronavirus patients with the combination of TFF2 protein and IFN-κ protein. [Figure 7] FIG. 7 shows the effect of a combination of TFF2 protein and IFN-κ protein on the length of hospital stay of novel coronavirus patients. [Figure 8] FIG. 8 shows the effect of a combination of TFF2 protein and IFN-κ protein on white blood cell counts in patients with novel coronavirus. [Figure 9] FIG. 9 shows the effect of a combination of TFF2 protein and IFN-κ protein on lymphocyte counts in patients with novel coronavirus. [Figure 10] FIG. 10 shows the effect of a combination of TFF2 protein and IFN-κ protein on C-reactive protein (CRP) in patients with novel coronavirus. [Figure 11]FIG. 11 shows the effect of a combination of TFF2 protein and IFN-κ protein on hemoglobin in patients with novel coronavirus. [Figure 12] FIG. 12 shows the effect of a combination of TFF2 protein and IFN-κ protein on platelet counts in patients with novel coronavirus. [Figure 13] FIG. 13 shows the number of days required to improve CT in novel coronavirus patients by treatment with a combination of TFF2 protein and IFN-κ protein and treatment with hydroxychloroquine. [Figure 14] FIG. 14 shows the effect of treatment with a combination of TFF2 protein and IFN-κ protein and treatment with hydroxychloroquine on the length of hospital stay in patients with novel coronavirus. [Figure 15] FIG. 15 shows the number of days required to eliminate cough in COVID-19 patients treated with a combination of TFF2 protein and IFN-κ protein and with hydroxychloroquine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] In each figure, * means p<0.05, ** means p<0.01, *** means p<0.001, and NC means conventional treatment control.
[0035] Specific embodiments The applicant has developed a TFF2 protein preparation and an IFN-κ protein preparation through long-term and thorough research, and unexpectedly found that the combination of these two drugs has a remarkable therapeutic effect in treating novel coronavirus infection and related diseases, and the effect is even better than that of the currently recommended drug hydroxychloroquine;In addition, these two proteins are proteins present in the human body, and the results of clinical trials have also proven that they have low toxicity to the human body, so the safety of the combination drug is also high.Based on related research, the present disclosure provides a combination of TFF2 protein and IFN-κ protein, its application in preparing a drug for treating novel coronavirus infection and its related diseases, and the corresponding treatment method.
[0036] All numerical ranges provided herein are intended to explicitly include all numerical values between the endpoints of the range and the numerical range therebetween. Features mentioned in this disclosure or in the examples can be combined. All features disclosed herein can be used in any combination, and each feature disclosed in the specification can be replaced with any alternative function that can provide the same, equal, or similar purpose. Thus, unless otherwise specified, the features disclosed are merely generic examples of equivalent or similar functions.
[0037] As used herein, "unit dose" and "unit dosage form" refer to a single drug administration entity.
[0038] As used herein, "about" before or after a numerical value or range means ±10% of the recited or claimed numerical value or range.
[0039] It should be understood that when a parameter range is provided, the invention also provides all integers within the range and one decimal place therein. For example, "0.1-2.5 mg / day" includes 0.1 mg / day, 0.2 mg / day, 0.3 mg / day, etc., up to 2.5 mg / day. The same applies to ratio ranges.
[0040] As used herein, the terms "comprise", "contain", and "have" include "comprise", "consist mainly of", "consist essentially of" and "consist of"; "consist mainly of", "consist essentially of" and "consist of" are subordinate concepts to "comprise", "contain", and "have".
[0041] Trefoil Factor 2 protein (TFF2 protein) Trefoil Factor 2 protein (TFF2 protein) was isolated from porcine pancreas by Jorgensen et al. in 1982 and is highly conserved in various species. Human Trefoil Factor 2 (hTFF2) and mouse Trefoil Factor 2 (mTFF2) contain the same number of amino acids, and the amino acid sequence homology reaches 82%. The mature TFF2 protein is composed of 106 amino acids, has a molecular weight of about 7-12 kD, contains four exons and two symmetric Trefoil domains, so its structure is very stable and resistant to acid, heat, and protease hydrolysis, and is mainly expressed in goblet cells in the neck of the gastric mucosa.
[0042] As used herein, the terms "Trefoil Factor 2 protein," "TFF2 protein," and "TFF2 polypeptide" are used interchangeably and refer to a class of polypeptides having the amino acid sequence set forth in SEQ ID NO:1 (human origin) or SEQ ID NO:2 (mouse origin), or a homologous sequence thereof. The term may include TFF2 polypeptides from various mammals, e.g., TFF2 polypeptides from human, mouse, rat, etc. The homology between TFF2 proteins may be 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
[0043] As used herein, the terms "nucleic acid molecule encoding TFF2", "sequence encoding TFF2" or "TFF2 gene" are used interchangeably and refer to a sequence encoding a TFF2 protein or polypeptide as described in the present disclosure. The nucleic acid molecule may be selected from, for example, the sequence of SEQ ID NO:3 (full human sequence), the sequence of SEQ ID NO:4 (human cDNA sequence), the sequence of SEQ ID NO:5 (full mouse sequence), the sequence of SEQ ID NO:6 (mouse cDNA sequence), molecules hybridizing to these sequences under stringent conditions, or family gene molecules highly homologous to the above molecules, and the expression of the above genes has a certain regulatory effect on the occurrence and effects of inflammation.
[0044] As used herein, the term "stringent conditions" refers to (1) hybridization and elution at lower ionic strength and higher temperature, e.g., 0.2xSSC, 0.1% SDS, 60°C; or (2) addition of a denaturing agent during hybridization, e.g., 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C; or (3) hybridization occurs only if the two sequences are at least 50%, preferably 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, or 90% or more, more preferably 95% identical. For example, the above sequence may be a complementary sequence of the sequence defined in (a).
[0045] The full-length nucleotide sequence of the TFF2 gene of the present disclosure or a fragment thereof can be obtained generally by PCR amplification, recombinant methods or artificial synthesis.For example, for PCR amplification, primers can be designed according to the nucleotide sequence, particularly the open reading frame sequence, disclosed in the present text or other databases, and a commercially available cDNA library or a cDNA library prepared by a person skilled in the art according to a general method known to those skilled in the art can be used as a template to obtain the relevant sequence by amplification.When the sequence is long, two or more PCR amplifications are often performed, and the fragments amplified in each round are joined in the correct order.
[0046] It should be understood that the nucleic acid encoding TFF2 of the present disclosure can be obtained from humans, and other genes obtained from other animals that are highly homologous to the human TFF2 gene (e.g., have sequence identity of 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more) are also within the scope of equivalence contemplated by the present disclosure. Methods and tools such as BLAST for aligning sequence identity are also well known in the art.
[0047] The TFF2 protein of the present disclosure may be a protein encoded by the encoding nucleic acid molecule described above (e.g., the encoding nucleic acid molecule of SEQ ID NO:3-6), or a homologous sequence (e.g., a homologous sequence of TFF2 can be obtained through database or alignment software known in the art), variant, or modified form of these proteins that have anti-inflammatory effects. For example, the TFF2 protein can be selected from (a) the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2; or (b) a protein or polypeptide derived from (a), which has one or more amino acid substitutions, deletions, or additions to the amino acid sequence of (a) and has anti-inflammatory activity.
[0048] Mutations of the proteins or polypeptides of the present disclosure include, but are not limited to, one or more (generally 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions, insertions and / or substitutions, and additions of one or more (generally 20 or less, preferably 10 or less, more preferably 5 or less) amino acids at the C-terminus and / or N-terminus. For example, substitutions with amino acids of similar characteristics in the art generally do not alter the function of the protein or polypeptide. However, additions of one or more amino acids at the C-terminus and / or N-terminus generally do not alter the function of the protein or polypeptide, e.g., the TFF2 protein or polypeptide of the present disclosure may or may not include an initial methionine residue and still have inflammation-modulating activity.
[0049] Depending on the host used in a recombinant production protocol, the proteins or polypeptides of the present disclosure may be glycosylated or non-glycosylated. The term also includes active fragments and active derivatives of the TFF2 protein.
[0050] Variant forms of the polypeptide include homologous sequences, conservative variants, allelic variants, naturally occurring mutants, induced mutants, and proteins encoded by sequences capable of hybridizing to sequences encoding the TFF2 protein under high or low stringency conditions, and polypeptides or proteins obtained using antisera against the TFF2 protein.
[0051] Interferon-kappa protein (IFN-kappa protein) IFN-κ consists of 207 amino acids, has a molecular weight of about 25 kDN, and contains a 27 amino acid signal peptide at the N-terminus. It is a more conservative and older type I interferon that belongs to the type I interferon family along with IFN-α and IFN-β. IFN-κ is mainly expressed in epithelial keratinocytes, transmits downstream signals via IFNAR1 and IFNAR2, activates ISGs, and exerts antiviral effects.
[0052] As used herein, the terms "interferon-kappa protein," "IFN-kappa polypeptide," and "IFN-kappa protein" are used interchangeably and refer to a class of polypeptides having the amino acid sequence set forth in SEQ ID NO:7 (human origin) or SEQ ID NO:2 (mouse origin), or a homologous sequence thereof. The term may include IFN-kappa polypeptides from various mammals, e.g., IFN-kappa polypeptides from humans, mice, rats, etc. The homology between IFN-kappa proteins may be 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%.
[0053] As used herein, the terms "nucleic acid molecule encoding IFN-κ", "sequence encoding IFN-κ" or "IFN-κ gene" are used interchangeably and refer to a sequence encoding an IFN-κ protein or polypeptide as described in the present disclosure. The nucleic acid molecule may be selected from, for example, the sequence of SEQ ID NO:9 (full human sequence), the sequence of SEQ ID NO:10 (human cDNA sequence), the sequence of SEQ ID NO:11 (full mouse sequence), the sequence of SEQ ID NO:12 (mouse cDNA sequence), a molecule hybridizing to these sequences under stringent conditions (e.g., the stringent conditions described above), or a family gene molecule highly homologous to the above molecules, and expression of the above genes can activate ISGs and exert an antiviral effect.
[0054] The full-length nucleotide sequence of the IFN-κ gene of the present disclosure or a fragment thereof can be obtained generally by PCR amplification, recombinant methods, or artificial synthesis. For example, for PCR amplification, primers can be designed according to the nucleotide sequence, particularly the open reading frame sequence, disclosed in the present text or other databases, and a commercially available cDNA library or a cDNA library prepared by a person skilled in the art using a common method known to those skilled in the art can be used as a template to obtain the relevant sequence by amplification. If the sequence is long, two or more rounds of PCR amplification are often performed, and the fragments amplified each time are joined in the correct order.
[0055] It should be understood that the IFN-κ-encoding nucleic acids of the present disclosure can be obtained from humans, and other genes obtained from other animals that are highly homologous to the human IFN-κ gene (e.g., having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% sequence identity) are also within the scope of equivalence contemplated by the present disclosure. Methods and tools such as BLAST for aligning sequence identity are also well known in the art.
[0056] The IFN-κ protein of the present disclosure may be a protein encoded by the encoding nucleic acid molecule described above (e.g., the encoding nucleic acid molecule of SEQ ID NO:9-12), or a homologous sequence of these proteins (e.g., a homologous sequence of IFN-κ can be obtained through databases or alignment software known in the art), variant, or modified form having anti-inflammatory effect. For example, said IFN-κ protein can be selected from (a) the amino acid sequence shown in SEQ ID NO:7 or SEQ ID NO:8; or (b) a protein or polypeptide derived from (a) having one or more amino acid substitutions, deletions or additions to the amino acid sequence of (a) and having anti-inflammatory activity.
[0057] Mutations of the proteins or polypeptides of the present disclosure include, but are not limited to, one or more (generally 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions, insertions and / or substitutions, and additions of one or more (generally 20 or less, preferably 10 or less, more preferably 5 or less) amino acids at the C-terminus and / or N-terminus. For example, substitutions with amino acids of similar properties in the art generally do not alter the function of the protein or polypeptide. However, additions of one or more amino acids at the C-terminus and / or N-terminus generally do not alter the function of the protein or polypeptide, e.g., the IFN-κ proteins or polypeptides of the present disclosure may or may not include an initial methionine residue and still have inflammatory factor suppression activity.
[0058] Depending on the host employed in a recombinant production protocol, the proteins or polypeptides of the present disclosure may be glycosylated or non-glycosylated. The term also includes active fragments and active derivatives of the IFN-κ protein.
[0059] Variant forms of the polypeptide include homologous sequences, conservative variants, allelic variants, naturally occurring mutants, induced mutants, and proteins encoded by sequences capable of hybridizing to sequences encoding IFN-κ protein under high or low stringency conditions, and polypeptides or proteins obtained using antisera against IFN-κ protein.
[0060] Anti-new coronavirus infection application As used herein, the term "treatment" includes (1) preventing or delaying the onset of clinical symptoms of a disease, disorder or condition in an animal (particularly a mammal, particularly a human) that may be suffering from or susceptible to a disease, disorder or condition, but that has not yet experienced or exhibited clinical or subclinical symptoms of the disease, disorder or condition; (2) inhibiting the disease, disorder or condition (e.g., halting, alleviating or delaying the progression or recurrence of the disease (in the case of maintenance therapy) or at least one of its clinical or subclinical symptoms); and / or (3) alleviating the symptoms (i.e., causing regression of the disease, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to the patient receiving the treatment is statistically significant or at least discernible by the patient or the physician.
[0061] In some embodiments, the combination comprising TFF2 protein and IFN-κ protein can effectively alleviate novel coronavirus infection and its associated diseases, such as novel coronavirus pneumonia and its symptoms.In one embodiment, the symptoms are dyspnea, hypoxemia, acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulopathy, multiple organ failure, pulmonary fibrosis, chronic inflammation with long-term onset, fever, dry cough, fatigue, stuffy nose, runny nose, sore throat, muscle pain, and diarrhea.
[0062] In some embodiments, the combination of the TFF2 protein and IFN-κ protein of the present disclosure may be used to treat various clinical classifications of novel coronavirus pneumonia, for example, mild, common, severe, and critical.
[0063] Combinations of TFF2 and IFN-κ proteins and products The present disclosure provides a combination comprising a therapeutically effective amount of a TFF2 protein and an IFN-κ protein, and an optional pharma- ceutically acceptable carrier. In some embodiments of the present disclosure, the combination is used to treat novel coronavirus infection and its associated diseases. In some embodiments of the present disclosure, the combination may be a drug composition, a formulation combination, a kit, or an in-use combination.
[0064] As used herein, the term "drug composition" refers to a drug combination comprising TFF2 protein and IFN-κ protein at the same time. As used herein, the term "combined formulation" or "kit" refers to a combination of TFF2 protein and IFN-κ protein that can be administered independently, in separate forms, or in different fixed combinations with independent amounts of active ingredients. In the combination, the ratio of the amount of IFN-κ protein administered to the amount of TFF2 protein can be varied to meet the needs of a subgroup of subjects to be treated or the needs of an individual subject, which may vary depending on the age, sex, weight, etc. of the subject. Each part of the kit can be administered simultaneously or chronologically staggered, for example, at different times and with the same or different time intervals for any part of the kit. Thus, the present disclosure relates to a combination of TFF2 protein and IFN-κ protein, for example, a combined formulation or drug composition, for simultaneous, separate, or sequential use.
[0065] The combination can also be used as an add-on therapy. As used herein, "add-on" or "add-on therapy" refers to a collection of drugs used in a therapy, where a subject undergoing this treatment starts a second regimen of one or more different drugs in addition to the first regimen after initiation of a first regimen of one or more drugs, and thus not all drugs used in the therapy are started at the same time. For example, IFN-κ protein therapy is added to a patient who has already received TFF2 protein therapy, or vice versa.
[0066] In some embodiments, the active agents in the combination or product of the present disclosure comprise a TFF2 protein and an IFN-κ protein. In some embodiments, the active agents in the combination or product of the present disclosure consist essentially of a TFF2 protein and an IFN-κ protein, or consist of a TFF2 protein and an IFN-κ protein.
[0067] As used herein, the terms "comprise" or "having" include "comprise", "consist essentially of" and "consist of". As used herein, a "pharmaceutically acceptable" ingredient is one that may be administered to humans and / or animals without undue adverse side effects (e.g., toxicity, irritation and allergic reactions), i.e., with a reasonable benefit / risk ratio. As used herein, the term "effective amount" is an amount that is functional or active in humans and / or animals and tolerated by humans and / or animals.
[0068] The active substance in the combination or product of the present disclosure accounts for 0.01-100% by weight of the total weight of the drug or composition, with the remainder being pharma- ceutically acceptable carriers and other additives and other substances. For example, if the drug or composition is a solution containing an active protein, the active protein may account for 0.01-100% by weight of the total weight; if the drug or composition is a powder, it may consist essentially or entirely of the active protein.
[0069] In some embodiments, the active ingredients in the combination or product of the present disclosure are present in an amount that produces a superior or synergistic therapeutic effect, including, but not limited to, a significant reduction in time to remission of disease symptoms, such as time to imaging improvement, time to cough resolution, and / or patient hospitalization, as compared to treatment with a therapeutically effective amount of hydroxychloroquine (e.g., a 100 mg dose orally once daily).
[0070] In some embodiments, the amount of TFF2 protein in the combination or product of the present disclosure ranges from 0.1 to 100 mg, 0.5 to 50 mg, 1 to 40 mg, or 5 to 30 mg. In some embodiments, the amount of IFN-κ protein in the combination of the present disclosure ranges from 0.01 to 100 mg, 0.05 to 80 mg, 0.1 to 70 mg, or 0.5 to 50 mg. In some embodiments, the amount of IFN-κ protein is 1x10 4 ~1x10 8 Activity units, 5x10 4 ~5x10 7 Activity unit, 1x10 5 ~1x10 7 Activity units, 5x10 5 ~5x10 6 It is an activity unit.
[0071] In some embodiments, the mass ratio of TFF2 protein to IFN-κ protein in a combination or product of the present disclosure is 1:100-100:1, 1:50-50:1, 1:10-10:1, 1:5-5:1, 1:2-2.5:1, or 1:1-2:1.
[0072] As used herein, the term "pharmaceutical acceptable carrier" refers to a carrier used in administering a therapeutic agent, and includes various excipients and diluents. The term refers to some pharmaceutical carriers that are not themselves essential active ingredients, but are not excessively toxic after administration. Suitable carriers are well known to those skilled in the art. A thorough discussion of pharmaceutical acceptable excipients can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ 1991).
[0073] In the pharmaceutical combination, drug composition or kit, the pharma- ceutically acceptable carrier may include liquids such as water, saline, glycerol and ethanol. In addition, these carriers may also include auxiliary substances such as fillers, disintegrants, lubricants, glidants, foaming agents, wetting or emulsifying agents, flavorings, pH buffering substances, etc. In general, these materials are non-toxic, inert, and can be formulated in a pharma- ceutically acceptable aqueous carrier medium, usually at a pH of about 5-8, preferably about 6-8.
[0074] As used herein, the term "unit dosage form" refers to the preparation of a composition of the present disclosure into a dosage form required for a single administration for ease of administration, and includes, but is not limited to, a variety of solid forms (such as powders), liquid forms, aerosols, capsules, and sustained release forms.
[0075] In another preferred embodiment of the present disclosure, the composition is in a unitary dosage form or a multi-dosage form, in which the amount of TFF2 protein ranges from 0.1 to 100 mg / dose, 0.5 to 50 mg / dose, 1 to 40 mg / dose, or 5 to 30 mg / dose; the amount of IFN-κ protein ranges from 0.01 to 100 mg / dose, 0.05 to 80 mg / dose, 0.1 to 70 mg / dose, or 0.5 to 50 mg / dose; or the amount of IFN-κ protein ranges from 1x10 4 ~1x10 8 Active units / agent, 5x10 4 ~5x10 7 Active units / agent, 1x10 5 ~1x10 7 Active units / agent, 5x10 5 ~5x10 6 Activity units / agent.
[0076] In some embodiments of the present disclosure, a subject can be administered an active agent of the present disclosure as needed, for example, 1-6, 1-3, or 1 product of the present disclosure administered daily, every 2 days, every 3 days, or weekly.
[0077] It should be understood that the effective dose of the active substance used may vary depending on the severity of the subject to be administered or treated.The specific situation is determined according to the subject's individual condition (e.g., subject's weight, age, physical condition, and desired effect), which is within the judgment of a skilled physician.
[0078] The administration route of the drug or drug composition or kit of the present disclosure includes, but is not limited to, one or more of the following: aerosol inhalation, nasal drops, topical administration, target tissue administration, injection, oral administration, etc. The TFF2 protein and the IFN-κ protein, or a formulation or composition containing the above proteins, can be administered simultaneously or separately by the same or different methods.
[0079] Administration of a combination comprising a TFF2 protein and an IFN-κ protein provides a beneficial, e.g., synergistic therapeutic effect, or other unexpected beneficial effect (e.g., substantially greater efficacy than existing drugs, fewer and / or milder side effects, etc.) compared to monotherapy using only a single active agent.
[0080] A combination including a TFF2 protein and an IFN-κ protein includes subeffective doses of the TFF2 protein and the IFN-κ protein, but can achieve the same effect as an effective dose of either single compound. Compared to monotherapy using only the IFN-κ protein or the TFF2 protein, lower doses of the TFF2 protein and the IFN-κ protein can be used. For example, not only can the doses used be reduced, but the frequency of use can also be reduced. Furthermore, the occurrence of side effects can be reduced and / or the response rate to the IFN-κ protein or the TFF2 protein-based therapy can be increased. All in line with the expectations and requirements of the patient to be treated.
[0081] In some embodiments, known clinical classification methods and indicators can be used to judge the therapeutic effect of the combination of the present application, for example, see "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)". In some embodiments, the combination of TFF2 protein and IFN-κ protein reduces the incidence, severity, and shortens the treatment course of diseases or symptoms. EXAMPLES
[0082] The present disclosure will be further described below with reference to specific examples. It should be understood that these examples do not limit the scope of the present disclosure, but are merely illustrative of the present disclosure. Those skilled in the art can make appropriate modifications and variations to the present disclosure, and all of these modifications and variations are within the scope of the present disclosure.
[0083] For the experimental methods not specified in the following examples, refer to, for example, "Laboratory Guide to Molecular Cloning" (3rd ed., New York: Cold Spring Harbor Laboratory Press, 1989), or use conventional methods in the field, such as following the conditions suggested by the supplier. DNA sequencing is a common method in the art, and tests can also be provided by commercial companies.
[0084] Unless otherwise specified, percentages and parts refer to weight.Unless otherwise defined, all technical and scientific terms used herein are consistent with the meanings known to those skilled in the art.In addition, any methods and materials similar or equivalent to those described can be applied to the methods of the present disclosure.The preferred embodiments and materials described herein are for illustrative purposes only.
[0085] Example 1. Expression and purification of TFF2 protein Step 1: Optimization of the preparation scheme of recombinant human TFF2 protein After cloning the gene according to the TFF2 sequence and transfecting the recombinant pSV1.0-TFF2 plasmid into 293T cells, the eukaryotic expression of TFF2 protein was detected by WB, and then eluted from the nickel column using various concentration gradients of imidazole to recover the target protein, followed by filtration and washing to obtain high-purity TFF2 protein, the specific procedures were as follows: PCR amplification was performed using cDNA generated by reverse transcription of RNA extracted from H9N2-infected mouse lung tissue as a template: Upstream primer (SEQ ID NO:13): 5'-CGCTCTAGAATGCGACCTCGAGGTGCCCC-3', Downstream primer (SEQ ID NO:14): 5'-CCTGGATCCTCAGTAGTGACAATCTTCCA-3'.
[0086] The amplification program was: pre-denaturation at 95°C for 2 min; denaturation at 95°C for 15 s; annealing at 55°C for 30 s; extension at 72°C for 30 s; final extension at 72°C for 10 min; cycle number 30. After the amplification was completed, the target gene was separated on a 1% agarose gel and the amplified product TFF2 was recovered using a Sanprep column DNA gel recovery kit. Both the TFF2 recovery and the vector pSV1.0 were recovered by double digestion with endonucleases BamHI and XbaI. After enzymatic digestion in a 37°C water bath for 7 h, the fragments were electrophoresed on a 1% agarose gel and recovered using a Sanprep column DNA gel recovery kit. The target fragment TFF2 was ligated with the vector pSV1.0 overnight at 4°C to form the recombinant plasmid pSV1.0-TFF2. The recombinant plasmid was transformed into E. coli TOP10, and positive clones were identified by colony PCR and double digestion (BamHI, XbaI). Sequencing confirmed that the target sequence was completely correct and no mutations were generated.
[0087] The correctly sequenced recombinant plasmid pSV1.0-TFF2 was transfected into 293FT cells, and after 72 hours of incubation in a 37°C incubator with TurboFect as the transfection reagent and DMEM complete medium (10% FBS and 1% PS) as the medium, the cells were removed and collected in a pre-cooled EP tube, the cells were lysed with RIPA lysis buffer, 5×SDS loading buffer was added to the supernatant, and the proteins were denatured by heating in a boiling water bath for 10 minutes, and after a short centrifugation, the supernatant was used as a spotting sample. The proteins were then separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the separation gel concentration was 15%. The electrophoresis voltage was 70V, and the time was 30-40 min (the time when the marker begins to separate was the mark). After the bromophenol blue migrated out of the stacking gel, the voltage was adjusted to 110V, and the power was turned off after 1 h 30 min, and the membrane was transferred. The current was constant at 200 mA, and the time was 1.5 h. After transferring to the membrane, the PVDF front membrane (the side in contact with the gel) was marked, placed in 5% nonfat dry milk, and blocked at room temperature for 1 h. Then, the primary antibody was added at the appropriate dilution ratio (TFF2: 1:400 or β-actin: 1:1000), diluted with 5% nonfat dry milk, and incubated overnight at 4 °C on a shaker. After washing the membrane with 0.05% PBST, secondary antibodies, TFF2-goat anti-rabbit (1:3000); β-actin-goat anti-mouse (1:3000), were added and diluted with 5% skim milk powder. The mixture was incubated on a shaker at room temperature for 1 hour, after which the membrane was washed, the membrane was developed, and the film was exposed to a quantitative analyzer for 2 minutes, and the developed results were recorded and analyzed.
[0088] The results showed that the cells expressed a large amount of TFF2 protein, which was secreted into the cell supernatant, and after concentration, the filtered effluent did not contain TFF2 protein. To quantify the concentration of TFF2, a standard curve of TFF2 was prepared using the SEA748MU ELISA kit for TFF2 purchased from USCN, and the concentration of TFF2 was quantified according to the optical density (OD) value of the standard.
[0089] Step 2: Preparation of recombinant human TFF2 protein Based on step 1, amplification preparation was performed, and 5 days after transfection into HEK293 cells, the cells were harvested and the protein expression status was detected by SDS-PAGE; The secretion supernatant was collected and purified by hydrophobic column, ion column purification steps to obtain the qualified protein product, which met the following quality criteria: protein concentration ≥ 0.5mg / ml, protein purity > 95%, endotoxin < 100Eu / mg, protein storage solution: PBS, pH 7.4; The entire amplification preparation process was performed in accordance with GMP standards.
[0090] After identification by SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining, the prepared TFF2 protein had a purity of over 95% and was transported in the form of a lyophilized powder at low temperature. Using an in vitro cell line, it was confirmed that it could stimulate the proliferation of MCF7 cells, with a half-effective dose of 11 ng / mL (see Figure 1).
[0091] TFF2 protein amino acid sequence The amino acid sequence of the resulting TFF2 protein is shown below (SEQ ID NO:1): EKPSPCQCSRLSPHNRTNCGFPGITSDQCFDNGCCFDSSVTGVPWCFHPLPKQESDQCVMEVSDRRNCGYPGISPEECASRKCCFSNFIFEVPWCFFPKSVEDCHY Example 2. Expression and purification of IFN-κ protein Step 1: Optimization of the preparation scheme of recombinant human IFN-κ protein IFN-κ was cloned from the human genome, the nucleotide sequence of its encoding gene is shown in SEQ ID NO:1, and the full-length amino acid sequence is shown in SEQ ID NO:2. IFN-κ belongs to the type I interferon family and shares only 30% homology with IFN-α and IFN-β.
[0092] A eukaryotic expression vector for IFN-κ was constructed to express the mature secreted protein in eukaryotic cell systems in vitro. Using the eukaryotic expression vector pSV1.0, an IFN-κ eukaryotic expression plasmid was constructed as follows: cDNA generated by reverse transcription of RNA extracted from A549 cells was used as a template to perform PCR amplification with the corresponding primers.
[0093] Upstream primer (SEQ ID NO:15): 5'- CGCTCTAGA ATGAGCACCAAACCTG-3', Downstream primer (SEQ ID NO:16): 5'-TCTGGATCCTTTATTTCCTCCTGAA-3'.
[0094] PCR reaction program: 95°C, 2 min; 35 cycles: 95°C, 15 sec; 55°C, 30 sec; 72°C, 30 sec; 72°C, 10 min; 4°C, 30 min.
[0095] After the amplification was completed, the target gene was separated on a 1% agarose gel, the gel was excised and collected, and the PCR fragment was collected using a Sanprep column DNA gel collection kit. Both the IFN-κ collection product and the pSV1.0 vector were double-digested with endonucleases BamHI and XbaI, and then the fragment and the vector were ligated with T4 DNA ligase at 4°C overnight. On the second day, the ligation product was transformed into E. coli TOP10 and grown overnight on kanamycin-containing plates. On the third day, single colonies were randomly picked for PCR identification, and then positive clones were selected for double enzyme digestion identification. The IFN-κ gene was successfully cloned after sequencing and correction of the mutation site to ensure that the entire sequence was correct. The cells and supernatants transfected with the pSV1.0-IFN-κ plasmid were collected and identified by Western blotting (WB), which showed that IFN-κ was expressed in both the cells and the supernatant.
[0096] Step 2: Preparation of recombinant human IFN-κ protein Based on step 1, amplification preparation was performed and protein expression status was detected by SDS-PAGE; The inclusion bodies were collected for refolding and purified by purification steps such as hydrophobic column, ionic column, etc. to obtain the qualified refolded protein product; Eligible protein products meet the following quality criteria: protein concentration ≥ 1mg / ml, protein purity > 95%, endotoxin < 100Eu / mg, protein storage solution: PBS, pH 7.4; The entire amplification preparation process was performed in accordance with GMP standards.
[0097] After identification by SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining, the product obtained by the above method had a purity of more than 95% and was transported at low temperature in the form of lyophilized powder. After activity detection by WISH-VSV method, its specific activity was 1.16x10 6 U / mg and further verified that purified IFN-κ protein can inhibit influenza virus PR8 replication in A549 cell line (see FIG. 2).
[0098] IFN-κ protein amino acid sequence The amino acid sequence of the resulting IFN-κ protein is shown below (SEQ ID NO:7): MLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK Example 3. Preparation of a formulation of TFF2 protein and IFN-κ protein The TFF2 protein and IFN-κ protein manufactured according to GMP standards in Example 1 and Example 2 were freshly prepared, using sterile water for injection, mixing 5 mg of TFF2 protein with 2 mg of IFN-κ protein, mixing 5 mg of TFF2 protein with 1 mg of IFN-κ protein, mixing 2 mg of TFF2 protein with 1 mg of IFN-κ protein, or compounding 5 mL solutions, placing them in sterile reagent bottles, storing at 4° C., and preparing immediately before use.
[0099] Example 4. Study of the efficacy and safety of the combination of TFF2 protein and IFN-κ protein in treating patients with COVID-19 This clinical study was approved by the Ethics Committee of Shanghai Public Health Clinical Center for ethical review, and the enrolled patients were recruited by Shanghai Public Health Clinical Center and all signed the informed consent.
[0100] Patient selection criteria 1. Age range: 18 to 70 years, regardless of gender; 2. Clinical diagnosis consistent with viral pneumonia: fever; normal or decreased white blood cell count with or without thrombocytopenia; presence of a consolidation on chest imaging; 3. Those who are etiologically positive for COVID-19; 4. Patients are able to receive aerosol inhalation therapy; 5. Gave consent to signing a written informed letter prior to starting the study.
[0101] Patient Exclusion Criteria 1. There is other evidence of pneumonia not caused by the new coronavirus; 2. There is clear evidence of bacterial infection; 3. Subjects who have used antiviral medication within 1 week prior to screening and who may require another antiviral treatment during the study; 4. Patients with severe underlying non-infectious pulmonary diseases such as pulmonary tuberculosis, pulmonary edema, or pulmonary embolism; 5. Severe liver and kidney dysfunction; 6. Participated or has participated in other clinical trials within 30 days prior to dosing; 7. Those with a history of allergy to interferon; 8. Pregnant (positive urine or serum pregnancy test) or lactating women; 9. Any person who is otherwise deemed by the investigator to be unsuitable for participation in this study, or who is deemed by the investigator to have a condition that may increase the risk to the subject or interfere with the clinical trial.
[0102] Basic information on the research subject and treatment methods Research subject information:
[0103] [Table 1]
[0104] Specific administration method Control group: Standard treatment was given, including hydroxychloroquine (i.e., hydroxychloroquine sulfate tablets), Lianhua Qingwen capsules, and other therapeutic drugs and methods recommended in the "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6)".
[0105] Experimental group: After patients were enrolled, they received aerosol inhalation treatment of 5 mg TFF2 protein and 1 mg IFN-κ protein on days 2, 4, and 6 in addition to conventional drug treatment. The 5:1 formulation prepared in Example 3 was poured into an atomizer cup, and the patients inhaled the aerosol for 20 to 30 minutes using an atomizer with a particle size of less than 5 μm.
[0106] [Table 2]
[0107] Clinical trial results The results of the efficacy study are shown in Figure 3-12. The results show that in the treatment of COVID-19 patients, the combination of IFN-k + TFF2 protein administered by aerosol inhalation can bring obvious clinical benefits, improve the patient's clinical symptoms, shorten the nucleic acid negative conversion time, recover lung function more quickly, significantly improve lung CT, shorten the hospital stay, shorten the cough disappearance time, rapidly increase white blood cells, and reduce the CRP response (which suggests a reduction in the production of inflammatory stress proteins), and has a certain clinical effect.
[0108] In addition, the study results showed that the ALT and AST levels in the aerosol treatment group were lower than those in the standard treatment group, indicating that aerosol inhalation did not damage the liver, and the levels of blood cells, platelets, and hemoglobin were comparable, indicating that aerosol inhaled drugs are also safe for blood function.
[0109] Study conclusions The results of clinical trials show that the combination treatment of TFF2 protein and IFN-κ protein can improve the symptoms of clinical patients, accelerate the improvement of nucleic acid negativity and lung CT, reduce the hospitalization time and cough time of patients, rapidly increase white blood cells, and reduce CRP response (which suggests a reduction in the production of inflammatory stress proteins). The effect of this drug combination is much better than that of traditional drug treatment of new coronavirus pneumonia.
[0110] Furthermore, combined treatment with TFF2 protein and IFN-κ protein can significantly increase the number of white blood cells in the blood, have no effect on lymphocytes, platelets, and heme, and can reduce the levels of AST, ALT, CRP, and TBiL to a certain extent within the physiological range, indicating no obvious toxicity to the liver, blood cells, and platelets.
[0111] In conclusion, the combination of TFF2 protein and IFN-κ protein can be effectively and safely used to treat novel coronavirus infection.
[0112] Example 5. Comparison of efficacy of TFF2 protein and IFN-κ protein in combination with hydroxychloroquine in patients with novel coronavirus Registered Subjects A typical patient with COVID-19.
[0113] Dosage regimen (1) Control group: standard treatment (except for administration of hydroxychloroquine), i.e., NC group; (2) Hydroxychloroquine group: 100 mg of hydroxychloroquine was orally administered once a day on top of standard care, i.e., “standard care plus hydroxychloroquine”; (3) TFF2+IFN-κ group: in addition to standard treatment, a combination formulation of 5 mg TFF2 protein + 1 mg IFN-κ protein was inhaled by aerosol, i.e., "standard treatment + protein combination aerosol"; (4) Comprehensive treatment group: In addition to standard treatment, 100 mg of hydroxychloroquine was orally administered once a day, and a combination preparation of 5 mg of TFF2 protein + 1 mg of IFN-κ protein was inhaled by aerosol, i.e., “standard treatment + hydroxychloroquine + (TFF2 protein + IFN-κ protein).”
[0114] Trial results and discussion The test results are shown in Figures 13-15. The results were as follows: Compared with the control group, the combination of TFF2 protein and IFN-κ protein and hydroxychloroquine treatment can both alleviate symptoms and accelerate recovery in patients with COVID-19, and the time to improvement of CT images, time to hospitalization, and time to disappearance of cough are shortened in the treatment group, but the combination of TFF2 protein and IFN-κ protein was more obvious.
[0115] Furthermore, compared with hydroxychloroquine treatment, the combination of TFF2 protein and IFN-κ protein significantly shortened hospital stay, significantly alleviated cough symptoms, and stably improved lung CT images.
[0116] In addition, the further combination of hydroxychloroquine with the combination of TFF2 protein and IFN-κ protein did not improve the therapeutic effect compared with the combination of TFF2 protein and IFN-κ protein, which further demonstrated the therapeutic effect of the combination of TFF2 protein and IFN-κ protein.
[0117] The above results indicate that the combination of TFF2 protein and IFN-κ protein can be effectively used to treat novel coronavirus pneumonia, and its effect is much better than that of the clinically recommended drug hydroxychloroquine. Considering that both TFF2 protein and IFN-κ protein are endogenous proteins, together with the safety profile shown above, the combination of these two proteins is expected to be a suitable drug for the treatment of novel coronavirus infection.
[0118] [Table 3]
[0119] All references mentioned in this disclosure are incorporated herein by reference as if each reference were incorporated by itself. It should be understood that based on the above disclosure, a person skilled in the art may make various changes or modifications to the present disclosure, and these equivalents are also included within the scope defined in the claims appended hereto.
Claims
1. (a) TFF2 protein; (b) an IFN-κ protein; and (c) An optional pharma- ceutically acceptable carrier. A product for treating COVID-19 and its associated symptoms in a subject, comprising:
2. 2. The product of claim 1, wherein said product is a pharmaceutical composition, a pharmaceutical combination or a kit.
3. The TFF2 protein is a human TFF2 protein or a mouse TFF2 protein; and / or The IFN-κ protein is a human IFN-κ protein or a mouse IFN-κ protein.
2. The article of claim 1 .
4. The TFF2 protein is selected from the polypeptides shown in SEQ ID NO: 1 or 2, or the polypeptides encoded by the nucleic acid molecules shown in any one of SEQ ID NO: 3-6; and / or The IFN-κ protein is selected from the proteins set forth in the sequence SEQ ID NO: 7 or 8, or the polypeptides encoded by the nucleic acid molecules set forth in any one of SEQ ID NO: 9-12.
2. The article of claim 1 .
5. The amount of TFF2 protein is 0.1-100 mg, 0.5-50 mg, 1-40 mg, or 5-30 mg; and / or 3. The product of claim 2, wherein the amount of IFN-κ protein is 0.01-100 mg, 0.05-80 mg, 0.1-70 mg, or 0.5-50 mg.
6. The product of claim 1, characterized in that the mass ratio of TFF2 protein to IFN-κ protein is 1:100-100:1, 1:50-50:1, 1:10-10:1, 1:5-5:1, 1:2-2.5:1, or 1:1-2:
1.
7. The product described in claim 1, which administers TFF2 protein and IFN-κ protein by the same or different routes selected from aerosol inhalation, nasal drops, spray, intravenous administration, administration into target tissue, or oral administration.
8. The product described in claim 1, which administers TFF2 protein and IFN-κ protein simultaneously, sequentially or at intervals.
9. The product according to any one of claims 1 to 8, which is prepared from TFF2 protein and IFN-κ protein, for use in treating COVID-19 and its associated symptoms in a subject.
10. COVID-19 and its associated symptoms are The product described in claim 9, characterized in that it is characterized by the following symptoms: novel coronavirus pneumonia; one or more symptoms associated with novel coronavirus infection selected from the following group: dyspnea, hypoxemia, acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation disorders, multiple organ failure, pulmonary fibrosis, chronic inflammation with long-term onset, fever, dry cough, fatigue, nasal congestion, runny nose, sore throat, muscle pain, and diarrhea.
11. 10. The article of manufacture of claim 9, wherein the subject is a human.
Citation Information
Patent Citations
Application of trefoil factor 2 in preparation of medicine for treating and preventing lung / bronchial acute inflammation diseases
CN105582526A
